Last 19 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.09 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 2.70 | 1.42 | 0.65 | 0.64 | 0.46 | 0.56 | 0.50 | 0.36 | 0.65 | 0.87 | 4.89 | 2.97 | 1.89 |
| — | +155.6% | +28.8% | +74.9% | -28.7% | -36.3% | -89.7% | -87.7% | -65.5% | -62.3% | +152.0% | -6.8% | +46.6% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | 552.43 | — | 0.98 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -52.1% | -14.9% | -15.4% | -14.5% | -9.1% | -13.7% | -8.9% | -13.7% | -13.8% | -14.1% | -12.8% | -14.7% | -18.6% |
| — | -8.4% | -73.0% | -5.6% | +34.2% | +2.8% | +30.8% | +7.0% | +25.6% | +18.0% | -8.7% | -43.9% | -112.1% | |
| ROA | -45.7% | -13.4% | -13.5% | -13.1% | -8.2% | -12.3% | -7.9% | -12.4% | -12.6% | -12.8% | -11.6% | -13.2% | -16.6% |
| — | -9.3% | -70.1% | -5.7% | +34.6% | +3.9% | +31.4% | +6.5% | +24.5% | +19.2% | -3.7% | -34.1% | -97.7% | |
| ROIC | -61.1% | -25.8% | -18.5% | -16.2% | -10.4% | -15.2% | -11.2% | -16.7% | -15.1% | -14.1% | -13.1% | -17.8% | -24.2% |
| — | -69.6% | -64.6% | +3.1% | +31.2% | -8.0% | +14.2% | +6.0% | +37.6% | +27.4% | -1.6% | -53.2% | -69.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 81.2% YoY to 15.73x, strengthening the short-term liquidity position.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | 0.00 |
| — | — | — | — | — | — | — | — | — | — | — | — | +32.1% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.87 | 15.73 | 6.87 | 28.76 | 31.96 | 8.68 | 8.43 | 9.75 | 10.61 | 10.91 | 7.87 | 8.52 | 8.80 |
| — | +81.2% | -18.4% | +194.9% | +201.2% | -20.4% | +7.1% | +14.5% | +20.6% | +3.5% | -42.7% | -64.8% | -68.8% | |
| Quick Ratio | 6.87 | 15.73 | 6.87 | 28.76 | 31.96 | 8.68 | 8.43 | 9.75 | 10.61 | 10.91 | 7.87 | 8.52 | 8.80 |
| — | +81.2% | -18.4% | +194.9% | +201.2% | -20.4% | +7.1% | +14.5% | +20.6% | +3.5% | -42.7% | -64.8% | -68.8% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 19 years · Updated daily
Total return calculator · dividends reinvested
Calculate ReturnsDollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Compare NowQuick answers to the most common questions about buying ANTX stock.
AN2 Therapeutics, Inc.'s current P/E is -4.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking AN2 Therapeutics, Inc.'s business trajectory between earnings reports.